AI-Based Personalized Digital Management for High-Risk Pulmonary Nodule Follow-up
2026년 9월 1일 업데이트: Jianxing He, The First Affiliated Hospital of Guangzhou Medical University
AI-Based Personalized Digital Management to Improve Follow-up Care Adherence Among Patients With High-Risk Pulmonary Nodules: A Pragmatic Randomized Clinical Trial
The goal of this pragmatic clinical trial is to learn whether AI-based personalized digital management can help patients with high-risk pulmonary nodules complete appropriate follow-up care. The study will include adults aged 40 years or older whose pulmonary nodules were identified on chest CT scans already performed at the hospital for clinical care, health examinations, or other reasons. The hospital's AI-based lung nodule evaluation system will be used to identify nodules classified as high risk. Patients who have already completed follow-up or entered an active pulmonary nodule management pathway will not be included.
The main question this study aims to answer is:
- Does personalized digital management increase the proportion of patients who complete appropriate pulmonary nodule follow-up within 16 weeks after randomization compared with usual care?
Researchers will compare personalized digital management with usual care. Participants will be randomly assigned in a 1:1 ratio to one of the following groups:
- The personalized digital management group will receive individualized information about the pulmonary nodule and recommendations for appropriate follow-up through the hospital's official WeChat account.
- The usual care group will not receive the study-specific personalized digital message. Participants in both groups may continue to receive routine clinical care.
Participants will:
- Provide electronic informed consent
- Answer a brief questionnaire about pulmonary nodule care received outside the hospital and selected health information, including smoking history
- Continue their usual medical care
- Allow researchers to review relevant hospital records to determine whether pulmonary nodule follow-up was completed
The study will not arrange an additional initial chest CT solely for research purposes. Appropriate follow-up may include specialist evaluation, follow-up chest CT, PET/CT, tissue sampling, surgery, or a documented clinical decision that no further evaluation is needed. Researchers will also examine subsequent diagnostic procedures, lung cancer diagnoses, treatments, complications, and longer-term clinical outcomes.
연구 개요
연구 유형
중재적
등록 (추정된)
4000
단계
- 해당 없음
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Age 40 years or older.
- Completion of a chest CT at the study hospital for clinical care, health examination, or another reason.
- At least one pulmonary nodule classified as high risk by the Linc model, with a predicted malignancy probability of 75% or greater. The index CT, index nodule, model version, and risk score must be traceable.
- Follow-up management for the index nodule has not been completed before randomization, and the participant has not entered a clearly documented active pulmonary nodule management pathway.
- Ability to provide valid electronic informed consent and receive study messages through the hospital's official WeChat account.
Exclusion Criteria:
- Prior or current lung cancer, or ongoing diagnostic evaluation, treatment, postoperative care, or surveillance for the index nodule.
- Active malignancy for which the pulmonary nodule should be evaluated or managed as possible metastatic disease or within another established cancer care pathway.
- Completion before randomization of a qualifying chest CT, pulmonary nodule specialist or multidisciplinary team evaluation, PET/CT, tissue sampling, surgery or lesion-directed treatment, or verified clinical closure related to the index nodule.
- An existing valid order, appointment, referral, or documented active management plan for the index nodule, including active management by thoracic surgery, a pulmonary nodule clinic or multidisciplinary team, oncology, or radiation oncology.
- Maximum diameter of the index lesion greater than 30 mm. These patients will receive standardized safety notification and accelerated specialist referral and will not be randomized.
- Lung-RADS category 4B or 4X, or an equivalent highly suspicious finding, when Lung-RADS is applicable or can be reliably reconstructed, if clinical safety review determines that immediate notification or accelerated clinical care is required.
- Another major clinical safety, ethical, technical, or data-protection concern that cannot be reasonably mitigated.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Personalized Digital Management
Following common AI-based identification, eligibility confirmation, and randomization, participants assigned to this arm will receive personalized information about their high-risk pulmonary nodule and recommendations for appropriate specialist follow-up through the hospital's official WeChat account.
Participants will otherwise continue routine clinical care.
|
Shortly after randomization, participants receive a study-specific personalized digital message through the hospital's official WeChat account.
The message provides understandable information about the participant's AI-classified high-risk pulmonary nodule, explains that a high-risk classification does not establish a diagnosis of lung cancer, and recommends returning to a pulmonary nodule-related specialist for further evaluation.
Subsequent imaging, diagnostic procedures, treatment, or observation will be determined by the treating clinician using the official radiology report, prior imaging, and the participant's clinical condition.
Message delivery, opening, link clicks, and technical delivery failures will be recorded.
|
|
간섭 없음: Usual Care
Participants assigned to this arm will not receive the study-specific personalized digital information or follow-up recommendations after randomization.
They will continue routine clinical care.
Standard clinical communication and any necessary safety notifications will remain available.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pulmonary Nodule Follow-up Completion Within 16 Weeks After Randomization
기간: From randomization through 16 weeks (Day 112)
|
The proportion of all randomized participants who complete at least one qualifying pulmonary nodule follow-up event by Day 112.
Qualifying events include: (1) chest CT related to the index nodule; (2) pulmonary nodule specialist or multidisciplinary team evaluation with a documented assessment and management plan; (3) PET/CT; (4) bronchoscopy, percutaneous biopsy, or other tissue sampling; (5) surgery, image-guided ablation, or lesion-directed radiotherapy; or (6) documented clinical closure by a qualified clinician after adequate evaluation.
Orders or appointments alone do not count.
Patient refusal, loss to follow-up, or death alone do not constitute clinical closure.
The denominator includes all randomized participants analyzed according to assigned group.
Only hospital records or verified outside-hospital records count as completion.
|
From randomization through 16 weeks (Day 112)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Follow-up Completion Within 30 Days After Randomization
기간: From randomization through 30 days
|
Proportion of all randomized participants completing at least one qualifying A-F follow-up event, using the same event and evidence rules as the primary outcome.
|
From randomization through 30 days
|
|
Time From Recommended Management Due Date to First Follow-up Completion
기간: From randomization through Day 112
|
Difference in days between the first qualifying follow-up event and the prespecified due date.
Negative values indicate early completion; positive values indicate delay.
Limited to participants with a valid due date.
|
From randomization through Day 112
|
|
Time From Index Chest CT to First Follow-up Completion
기간: From index chest CT through Day 112
|
Days from the index chest CT to the first qualifying A-F event, described within prespecified 3-, 6-, or 12-month management strata.
|
From index chest CT through Day 112
|
|
Lung Cancer Diagnosis
기간: From randomization through 12 months
|
Proportion of all randomized participants meeting the prespecified lung cancer diagnosis standard.
Pathologic confirmation is preferred; adjudicated clinical diagnosis is permitted when prespecified criteria are met.
|
From randomization through 12 months
|
|
Diagnostic Closure
기간: From randomization through 12 months
|
Proportion achieving malignant diagnosis, specific benign diagnosis, or adequate clinical evaluation documenting that no further diagnostic work-up is required.
|
From randomization through 12 months
|
|
Stage of Diagnosed Lung Cancers
기간: From randomization through 12 months
|
Clinical and pathologic TNM stage distribution among diagnosed lung cancers, including the proportion diagnosed at stage I or II.
|
From randomization through 12 months
|
|
Histologic Type of Diagnosed Lung Cancers
기간: From randomization through 12 months
|
Distribution of histologic types among participants with pathologically confirmed lung cancer.
|
From randomization through 12 months
|
|
Invasive Procedures Related to the Index Nodule
기간: From randomization through 12 months
|
Proportion of all randomized participants undergoing bronchoscopy, percutaneous biopsy, surgical sampling or resection, or image-guided ablation related to the index nodule.
|
From randomization through 12 months
|
|
Complications Following an Invasive Procedure
기간: From randomization through 12 months
|
Proportion of all randomized participants experiencing prespecified related complications, including pneumothorax, bleeding, infection, hospitalization, intensive care, or death.
|
From randomization through 12 months
|
|
Benign Biopsy
기간: From randomization through 12 months
|
Proportion of all randomized participants undergoing tissue sampling with a final benign result and no lung cancer diagnosis during the prespecified follow-up.
|
From randomization through 12 months
|
|
Nondiagnostic Tissue Sampling
기간: From randomization through 12 months
|
Proportion of all randomized participants undergoing tissue sampling that does not establish a malignant or specific benign diagnosis.
|
From randomization through 12 months
|
|
Time From Index Chest CT to Lung Cancer Diagnosis
기간: From index chest CT through 12 months after randomization
|
Days from the index chest CT to the prespecified lung cancer diagnosis date.
|
From index chest CT through 12 months after randomization
|
|
Time From Randomization to Lung Cancer Diagnosis
기간: From randomization through 12 months
|
Days from randomization to the prespecified lung cancer diagnosis date.
|
From randomization through 12 months
|
|
Time From Recommended Due Date to Lung Cancer Diagnosis
기간: Through 12 months after randomization
|
Difference in days between the prespecified management due date and lung cancer diagnosis; limited to participants with a valid due date.
|
Through 12 months after randomization
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 10월 1일
기본 완료 (추정된)
2027년 4월 1일
연구 완료 (추정된)
2028년 10월 1일
연구 등록 날짜
최초 제출
2026년 9월 1일
QC 기준을 충족하는 최초 제출
2026년 9월 1일
처음 게시됨 (실제)
2026년 9월 4일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 9월 4일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 9월 1일
마지막으로 확인됨
2026년 9월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .